Cancer Monoclonal Antibodies Market 2020-2026
|出版商||Orion Market Research Pvt Ltd||商品編碼||986533|
|癌症治療單克隆抗體的全球市場預測（2020-2026） Cancer Monoclonal Antibodies Market 2020-2026|
|出版日期: 2020年11月11日||內容資訊: 英文||
在預測期內，估計用於癌症治療的單克隆抗體的全球市場將顯著增長。單克隆抗體越來越多的批准是推動市場增長的因素。從靶標開發到技術進步，單克隆抗體藥物已成為醫學領域的公認療法。截至2019年11月，美國FDA已批准了六種單克隆抗體療法： crizanlizumab, romosozumab, brolucizumab, risankizumab, polatuzumab vedotin,caplacizumab-yhdp (Cablivi)。單克隆抗體用於治療多種疾病，包括某些類型的癌症。
Global Cancer Monoclonal Antibodies Market Size, Share & Trends Analysis Report, By Type (Naked, Conjugated, and Others), By Application (Breast Cancer, Liver Cancer, Blood Cancer, Brain Cancer, Colorectal Cancer, and Others) and Forecast, 2020-2026
The global cancer monoclonal antibodies market is estimated to witness significant growth during the forecast period. Increasing approvals for monoclonal antibodies is driving the market growth. Monoclonal antibody drugs have become established therapy in the area of medicine ranging from development of targets to improvement in technologies. As of November 2019, the US FDA approved 6 monoclonal antibody therapeutics, which include crizanlizumab, romosozumab, brolucizumab, risankizumab, polatuzumab vedotin, and caplacizumab-yhdp (Cablivi). Monoclonal antibodies are used for the treatment of several diseases, which includes some kinds of cancer.
Researchers need to first identify the right antigen to attack to develop a monoclonal antibody. Monoclonal antibodies have demonstrated to be more beneficial against some cancers compared to others. Some monoclonal antibodies are used for the treatment of cancer are known as targeted therapy as they have a particular target on a cancer cell that intends to discover, attach to, and attack. However, other monoclonal antibodies works as immunotherapy as they supports to make the response of immune system better which in turn, supports the body to discover and attack cancer cells more potentially.
Geographically, Asia-Pacific cancer monoclonal antibodies market is estimated to witness potential growth during the forecast period owing to the increasing prevalence of cancer and emerging demand for novel cancer therapies in the region. As per the World Health Organization (WHO), the number of new cancer incidences in China were nearly 4.3 million in 2018. In India, the number of new cancer incidences were 1.2 million in 2018. This leads to an increasing demand for monoclonal antibodies therapy in the region for the treatment of both solid tumors and hematologic malignancies.
Some key players in the market include Amgen Inc., Eli Lilly & Co., F. Hoffman-La Roche AG, Merck & Co., Inc., and Novartis AG. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in June 2018, Pfizer Inc. declared the US FDA approval of ZIRABEV (bevacizumab-bvzr). It is a biosimilar to Avastin (bevacizumab) which is indicated to treat five kinds of cancer, including locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC), metastatic colorectal cancer, unresectable, metastatic renal cell carcinoma (RCC), recurrent glioblastoma; and persistent, recurrent or metastatic cervical cancer. It is the company's second oncology monoclonal antibody biosimilar gained FDA approval, following TRAZIMERA (trastuzumab-qyyp) in March 2019. This new biosimilar can support to increase access to impactful therapies, accelerating market competition. As a result, this may eventually reduce costs and support meet the diverse requirements of patients suffering from cancer.
The market study of the global cancer monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary Sources Include:
Financial reports of companies involved in the market.
Whitepapers, research-papers, and news blogs.
Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
1. Global Cancer Monoclonal Antibodies Market Research and Analysis by Type
2. Global Cancer Monoclonal Antibodies Market Research and Analysis by Application
The Report Covers:
Comprehensive research methodology of the global cancer monoclonal antibodies market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global cancer monoclonal antibodies market.
Insights about market determinants which are stimulating the global cancer monoclonal antibodies market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.